|
Novartis expects to sustain long-term growth with a robust pipeline of 25+ potential blockbusters
|
10 December 2019 |
|
Novartis announces new strategy to provide innovative medicines to more patients in sub-Saharan Africa
|
19 November 2019 |
|
Novartis Cosentyx® shows encouraging results versus Humira® from first-of-its-kind head-to-head trial in psoriatic arthritis
|
04 November 2019 |
|
Novartis announces that Jakavi® (ruxolitinib) meets primary endpoint in Phase III study of acute graft-versus-host disease
|
16 October 2019 |
|
Novartis and Microsoft announce collaboration to transform medicine with artificial intelligence
|
02 October 2019 |
|
Sandoz announces global deal to commercialize proposed biosimilar natalizumab, a key multiple sclerosis medicine
|
05 September 2019 |
|
FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)
|
16 July 2019 |
|
Novartis, Amgen and Banner Alzheimer's Institute discontinue clinical program with BACE inhibitor CNP520 for Alzheimer's prevention
|
11 July 2019 |
|
Novartis successfully completes acquisition of Xiidra®, bolstering ophthalmic portfolio
|
01 July 2019 |
|
Long-term survival benefit shown for metastatic melanoma patients treated with Novartis Tafinlar® + Mekinist®
|
06 June 2019 |